ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Approves Poteligeo (mogamulizumab-kpkc) for Mycosis Fungoides and Sézary Syndrome
August 09, 2018The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior syste
Pharma Sources Insight January 2025
